Navigation Links
Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Date:9/18/2007

LAKE FOREST, Calif., Sept. 18 /PRNewswire/ -- Worldwide markets of approved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007, pushing sales to more than $3.2 billion, exceeding total sales reported in 2005. Hundreds of clinical trials are ongoing, aimed at expanding indications for these drugs and fueling continued rapid market growth. In addition to the seven marketed ErbB-pathway inhibitors, more than 50 novel agents targeting this pathway are in development.

"The ErbB Pathway in Cancer" is a series of comprehensive reports published in Future Oncology, New Medicine's premiere newsletter. Future Oncology provides analysis of critical issues in global cancer R&D, clinical practices, markets, and business and company developments. The series covers every aspect of the EGFr/HEr2 inhibitor marketplace, including:

-- Markets (USA and ROW) of approved drugs and forecasts

-- Treatment costs in the USA and ROW

-- Detailed ErbB pathway analyses

-- Associations of ErbB expression and mutations with specific indications

-- EGFr/HEr2-based diagnostic/theragnostic technologies and products

-- Detailed profiles of currently approved drugs

-- Comprehensive reviews of current use of approved drugs by indication

-- Comprehensive reviews of new indications of approved drugs

-- Protocols and interim and final results from clinical trials combining

approved ErbB pathway inhibitors with novel agents.

-- Detailed profiles of over 50 agents in development targeting the ErbB

pathway, including protocols and interim and final results from

hundreds of trials

This series, published in 5 parts, is available for purchase in electronic PDF or hard copy format.


'/>"/>
SOURCE New Medicine
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
4. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
5. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
8. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
9. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
10. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
11. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... it’s been named Agency of Record (AOR) for Theravent, Inc. , the ... snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand distribution ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover ... O2X , an active lifestyle company that provides Human Performance Training and ... firefighters, police offers, first responders, military officers and others in service through the ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Alive for ... who wish to overcome their mental health struggles. The Alive team uses advanced ... says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... 21, 2017 , ... Northern California Medical Associates ... Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference plays ... an opportunity to learn about cutting edge treatments, to collaborate, share research and ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... practices, is seeking candidates to serve on its Accreditation and Standards Committees ... “RadSite’s ultimate mission is improving image quality and reducing patient radiation dose,” ...
Breaking Medicine News(10 mins):